Molecular profiling for personalized cancer care

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 653-655

  Ashfaq, Raheela ^a  

^a CARIS LIFE SCIENCES   (United States)

Author keywords

Clinical trials; Molecular diagnostics; Molecular profiling; Targeted therapies; Targets

Indexed keywords

CANCER CENTER; CONFERENCE PAPER; COPY NUMBER VARIATION; DIAGNOSTIC TEST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOLECULAR PROFILING; PATIENT CARE; PERSONALIZED MEDICINE; SENSITIVITY AND SPECIFICITY;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84868200881     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9483-3     Document Type: Conference Paper

References (23)

1. Ross JS (2011) Cancer biomarkers, companion diagnostics and personalized oncology. Biomarker Med 5(3):277-279
2. Macconaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28(35):5219-5228
3. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M (2010) Commentary: Tackling the challenges of developing targeted therapies for cancer. Oncologist 15(5):484-487
4. Dhani N, Tu D, Sargent DJ et al (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873-1882
5. Smith S, Su D, Rigault de la Longrais IA et al (2007) ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in additional to platinum-based therapy. J Clin Oncol 25:5172-5179
6. Iwao-Koizumi K, Matoba R, Ueno N et al (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431
7. Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747-2754
8. Kamel-Reid S, Zhang T, Persons DL, Nikiforova MN, Halling KC (2012) Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 136(1):26-32
9. Andre F, Mazouni C, Hortobagyi GN et al (2006) DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. Biochim Biophys Acta 1766:197-204
10. Sørlie T, Perou CM, Fan C et al (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5:2914-2918
11. Chang JC, Makris A, Gutierrez MC (2008) Gene expression patterns in formalin-fixed, paraffin embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 108:233-240
12. Dressman HK, Berchuck A, Chan G et al (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25:517-525
13. Kihara C, Tsunoda T, Tanaka T et al (2001) Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene expression profiles. Cancer Res 61: 6474-6479
14. Del Rio M, Molina F, Bascoul-Mollevi C et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25:773-780
15. Minna JD, Girard L, Xie Y (2007) Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 25: 4329-4336
16. Harris T, Atkins D et al (2001) Current methods of the U.S. preventive service task force. Am J Prev Med 20:21-35
17. Von Hoff DD, Penny R, Shack S et al (2006) Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. J Clin Oncol 24: 138 (suppl; abstr 3071)
18. Von Hoff DD, Stephenson JJ, Rosen PJ et al (2009) A pilot study utilizing molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. AACR Abstract, LB-259
19. Shacham-Shmueli E et al (2011) Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: A new approach in the era of personalized medicine? J Clin Oncol 29(10):e262-e265
20. Weiss GJ, Alardon A, Halepota M et al (2010) Molecular characterization of interdigitating cell sarcoma. Rare Tumors. doi: 10.4081/rt.2010.e50
21. Tsimberdou et al
22. Kim ES, Herbst RS, Lee JJ et al (2009) Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCL): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol 27:412 (suppl; abstr 8024)
23. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100